|
|||
|
Multiple Sclerosis Information
Favorite Links
This Month
Month Archive
|
Monday, April 20
Glatiramer Acetate for Clinically Isolated Syndrome
by
All About MS
on Mon 20 Apr 2009 12:05 PM CST
Health Canada has approved an expanded indication for glatiramer acetate injection (Copaxone) to include the treatment of patients who have experienced a single demyelinating event, accompanied by abnormal magnetic resonance imaging (MRI) more »
Thursday, April 16
natalizumab (Tysabri®) - technique to counteract serious side effects
by
All About MS
on Thu 16 Apr 2009 07:00 AM CST
Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri®), a drug that more »
Friday, April 10
Tysabri – Free of Relapses for 2 Years
by
All About MS
on Fri 10 Apr 2009 03:00 AM CST
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced five-times as many multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) were free from disease activity versus placebo in the overall patient population. Results more »
Thursday, April 9
Copaxone Approved for Clinical Isolated Syndrome
by
All About MS
on Thu 09 Apr 2009 08:16 AM CST
The Medicines and Healthcare products Regulatory Agency (MHRA) in the USA has approved an expanded label for glatiramer acetate (Copaxone) injection to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple more »
|
||
